SEC Comment Letter 0000000000-24-009351 to Biodexa Pharmaceuticals Plc (BDRX)
Biodexa Pharmaceuticals Plc
Date: Aug. 15, 2024 · CIK: 0001643918 · Accession: 0000000000-24-009351
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-281489
Letter
August 15, 2024 Stephen Stamp Chief Executive Officer Biodexa Pharmaceuticals Plc 1 Caspian Point Caspian Way Cardiff, CF10 4DQ, United Kingdom Re:Biodexa Pharmaceuticals Plc Registration Statement on Form F-1 Filed August 12, 2024 File No. 333-281489 Dear Stephen Stamp: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jason S. McCaffrey, Esq.
Show Raw Text
August 15, 2024
Stephen Stamp
Chief Executive Officer
Biodexa Pharmaceuticals Plc
1 Caspian Point
Caspian Way
Cardiff, CF10 4DQ, United Kingdom
Re:Biodexa Pharmaceuticals Plc
Registration Statement on Form F-1
Filed August 12, 2024
File No. 333-281489
Dear Stephen Stamp:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jason S. McCaffrey, Esq.